Montelukast Administration Timing for Optimal Therapeutic Benefit

Guideline-Based Recommendations and Clinical Trial Evidence

The American Academy of Allergy, Asthma, and Immunology supports the use of montelukast in the evening, as evidenced by clinical trials such as the CLIC and PACT trials, which administered montelukast as "5-10 mg nightly" or "5 mg in the evening" in children with persistent asthma, demonstrating significant improvements in symptom control 1, 2, 3, 4
Nighttime dosing has been shown to effectively address nocturnal symptoms, with studies demonstrating significant reductions in nighttime awakenings and improvement in morning peak flow rates, as seen in trials published in the Journal of Allergy and Clinical Immunology 1, 2

The pivotal adult asthma trials used "10 mg once daily at bedtime" dosing, demonstrating significant improvements in lung function, symptom control, and reduction in rescue medication use, although the specific trial details are not provided in this context 1, 2

The American Academy of Pediatrics recommends that montelukast should be taken in the evening or at bedtime 5
The medication can be taken without regard to meals, though administration with meals may improve gastrointestinal tolerability 6

No dose adjustment is required for patients with normal hepatic and renal function when used with other medications 7
Patients with moderate renal impairment may require dose adjustment, but the once-daily frequency remains unchanged 5

The FDA recommends monitoring patients for unusual behavioral or mood changes when starting montelukast 7
The FDA issued a black box warning regarding serious neuropsychiatric events including suicidal thoughts or actions 8, 7